A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

This study tests whether adding a new drug called SCTC21C to the standard three-drug combination (bortezomib, lenalidomide, and dexamethasone) is safe and effective for patients with newly diagnosed multiple myeloma who are not candidates for a stem cell transplant. **You may be eligible if...** - You have been newly diagnosed with multiple myeloma - You are not eligible for a stem cell transplant - Your disease shows measurable signs that can be tracked - Your organ function meets required levels - You are willing to use contraception as required **You may NOT be eligible if...** - You have previously been treated for multiple myeloma - You have serious heart, liver, or kidney disease - You are pregnant or breastfeeding - You have active infections or other conditions that make the treatment unsafe Talk to your doctor to see if this trial is right for you.